(1)
Caporali, R.; Ravasio, R.; Raimondo, P.; Salaffi, F. Cost Per Responder for Upadacitinib Vs Abatacept in Patients With Moderate-to-Severe Rheumatoid Arthritis in Italy. Grhta 2021, 8, 69-79.